Aptevo Therapeutics Inc.

APVOSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1671584

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	—	$3.1M	$12.3M	$4.3M	$4.3M
Cost of Goods and Services Sold	—	—	—	—	—
Research and Development Expense	$17.1M	$17.9M	$19.0M	$17.9M	$24.8M
Selling, General and Administrative Expense	—	—	—	—	—
Operating Income (Loss)	-$28.9M	-$28.6M	-$21.4M	-$27.5M	-$41.0M
Nonoperating Income (Expense)	—	—	—	—	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$18.6M	$7.0M	-$29.4M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$24.8M	$34.2M	$56.6M	$53.5M	$53.4M
Assets, Current	$19.1M	$27.4M	$52.6M	$47.3M	$30.0M
Cash and Cash Equivalents, at Carrying Value	$16.9M	$22.6M	$45.0M	$40.0M	$12.4M
Accounts Receivable, after Allowance for Credit Loss, Current	—	—	—	—	—
Inventory, Net	—	—	—	—	—
Liabilities	$12.6M	$16.2M	$55.4M	$37.0M	$41.6M
Liabilities, Current	$7.2M	$8.7M	$34.8M	$14.5M	$38.2M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$11.7M	-$21.0M	-$21.7M	-$29.3M	-$42.4M
Net Cash Provided by (Used in) Investing Activities	$0.00	-$29.0K	-$713.0K	$28.0M	$4.1M
Net Cash Provided by (Used in) Financing Activities	$6.0M	-$2.6M	$26.2M	$23.9M	$20.1M
Payments to Acquire Property, Plant, and Equipment	—	$29.0K	$713.0K	$88.0K	$153.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)